Compare · SMX vs TMO
SMX vs TMO
Side-by-side comparison of SMX (Security Matters) Public Limited Company (SMX) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- SMX operates in Technology, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $174.49B, about 27375.2x SMX ($6.4M).
- Over the past year, SMX is down 100.0% and TMO is up 11.5% - TMO leads by 111.4 points.
- SMX has been more active in the news (19 items in the past 4 weeks vs 6 for TMO).
- TMO has more recent analyst coverage (25 ratings vs 0 for SMX).
- Company
- SMX (Security Matters) Public Limited Company
- Thermo Fisher Scientific Inc
- Price
- $2.08-41.90%
- $469.57+0.63%
- Market cap
- $6.4M
- $174.49B
- 1M return
- -75.44%
- -4.31%
- 1Y return
- -99.99%
- +11.45%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 19
- 6
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest SMX
- Interim CFO Bader Amir was granted 200,000 units of Ordinary Shares, increasing direct ownership by 184% to 308,846 units (SEC Form 4)
- Chairman & CEO Alon Haggai was granted 2,000,000 units of Ordinary Shares, increasing direct ownership by 891% to 2,224,501 units (SEC Form 4)
- New insider Alon Haggai claimed ownership of 224,501 units of Ordinary Shares (SEC Form 3)
- New insider Bader Amir claimed ownership of 108,846 units of Ordinary Shares (SEC Form 3)
- SEC Form 6-K filed by SMX (Security Matters) Public Limited Company
- MEDIA ALERT: SMX Featured In Time Story On Recycled Plastics
- Made in America, for Real: Why Material Efficiency is Becoming a New Engine of U.S. Industrial Strength
- SMX Launches Digital Material Passport Platform (DMPP) Enabling Verified Material Identity, Traceability and Real-World Asset Digitization
- Make "Made In America" Great Again: How Material Efficiency Can Strengthen U.S. Industry In A Post-War World
- SMX Resets Plastic Economics-Lower Costs Start with Recycling
Latest TMO
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
- SEC Form 4 filed by Sperling Scott M
- SEC Form 4 filed by Keith R. Alexandra
- SEC Form 4 filed by Lynch Karen S